

# Rocco Lagioia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3370542/publications.pdf>

Version: 2024-02-01

42  
papers

1,224  
citations

430874

18  
h-index

377865

34  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1779  
citing authors

#	ARTICLE	IF	CITATIONS
1	Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. <i>European Heart Journal</i> , 2005, 26, 2232-2237.	2.2	246
2	Short-Term Change in Distance Walked in 6 Min Is an Indicator of Outcome in Patients With Chronic Heart Failure in Clinical Practice. <i>Journal of the American College of Cardiology</i> , 2006, 48, 99-105.	2.8	84
3	Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison. <i>European Journal of Heart Failure</i> , 2018, 20, 700-710.	7.1	84
4	Circulating microRNA-150-5p as a novel biomarker for advanced heart failure: A genome-wide prospective study. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 616-624.	0.6	70
5	Low-dose dobutamine responsiveness in idiopathic dilated cardiomyopathy: relation to exercise capacity and clinical outcome. <i>European Heart Journal</i> , 2000, 21, 927-934.	2.2	64
6	Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. <i>European Journal of Heart Failure</i> , 2019, 21, 208-217.	7.1	60
7	Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score. <i>International Journal of Cardiology</i> , 2013, 168, 2120-2126.	1.7	58
8	Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 76-84.	1.5	56
9	Prediction of mortality in mild to moderately symptomatic patients with left ventricular dysfunction. <i>European Heart Journal</i> , 1994, 15, 1089-1095.	2.2	54
10	Percent achieved of predicted peak exercise oxygen uptake and kinetics of recovery of oxygen uptake after exercise for risk stratification in chronic heart failure. <i>International Journal of Cardiology</i> , 1998, 64, 117-124.	1.7	30
11	Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. <i>European Journal of Internal Medicine</i> , 2020, 71, 23-31.	2.2	29
12	Prognostic role of $\beta$ -blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database. <i>European Journal of Heart Failure</i> , 2017, 19, 904-914.	7.1	28
13	Prediction of cardiac events after uncomplicated myocardial infarction by cross-sectional echocardiography during transesophageal atrial pacing. <i>International Journal of Cardiology</i> , 1990, 28, 95-103.	1.7	25
14	Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 1586-1595.	7.1	24
15	Inpatient Cardiac Rehabilitation Soon After Hospitalization for Acute Decompensated Heart Failure. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2012, 32, 71-77.	2.1	23
16	Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 368-377.	3.1	23
17	Propionil-L-carnitine: a new compound in the metabolic approach to the treatment of effort angina. <i>International Journal of Cardiology</i> , 1992, 34, 167-172.	1.7	22
18	The ADHF/NT-proBNP risk score to predict 1-year mortality in hospitalized patients with advanced decompensated heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 404-411.	0.6	21

#	ARTICLE	IF	CITATIONS
19	Ivabradine, coronary artery disease, and heart failure: beyond rhythm control. <i>Drug Design, Development and Therapy</i> , 2014, 8, 689.	4.3	18
20	Prognostic impact of comorbidities in hospitalized patients with acute exacerbation of chronic heart failure. <i>European Journal of Internal Medicine</i> , 2016, 34, 63-67.	2.2	18
21	Female gender and mortality risk in decompensated heart failure. <i>European Journal of Internal Medicine</i> , 2018, 51, 34-40.	2.2	16
22	Physical activity for coronary heart disease: cardioprotective mechanisms and effects on prognosis. <i>Monaldi Archives for Chest Disease</i> , 2005, 64, 77-87.	0.6	15
23	Predicting Short-Term Mortality in Advanced Decompensated Heart Failure—Role of the Updated Acute Decompensated Heart Failure/N-Terminal Pro-B-Type Natriuretic Peptide Risk Score. <i>Circulation Journal</i> , 2015, 79, 1076-1083.	1.6	15
24	Clinical outcomes, pharmacological treatment, and quality of life of patients with stable coronary artery diseases managed by cardiologists: 1-year results of the START study. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2019, 5, 334-342.	4.0	14
25	Systemic Vascular Hemodynamic Changes due to 17- $\beta$ -Estradiol Intranasal Administration. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 354-358.	2.0	13
26	Mineralocorticoid receptor antagonists for heart failure: a real-life observational study. <i>ESC Heart Failure</i> , 2018, 5, 267-274.	3.1	13
27	Dose-dependent efficacy of $\beta$ -blocker in patients with chronic heart failure and atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 273, 141-146.	1.7	13
28	Long-term prognostic role of diabetes mellitus and glycemic control in heart failure patients with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2020, 317, 103-110.	1.7	13
29	Predictors of Long-Term Mortality in Older Patients Hospitalized for Acutely Decompensated Heart Failure: Clinical Relevance of Natriuretic Peptides. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 822-826.	2.6	12
30	Detection and prognostic impact of renal dysfunction in patients with chronic heart failure and normal serum creatinine. <i>International Journal of Cardiology</i> , 2011, 147, 228-233.	1.7	10
31	Right heart dysfunction. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 613-623.	1.5	10
32	Renal Dysfunction and Accuracy of N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Mortality for Hospitalized Patients With Heart Failure. <i>Circulation Journal</i> , 2014, 78, 2439-2446.	1.6	9
33	Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. <i>Journal of Cardiac Failure</i> , 2020, 26, 932-943.	1.7	8
34	Acutely decompensated heart failure with chronic obstructive pulmonary disease: Clinical characteristics and long-term survival. <i>European Journal of Internal Medicine</i> , 2019, 60, 31-38.	2.2	6
35	The prophylaxis of infective endocarditis: a joint position study of the Italian Federation of Cardiologists and the Italian Society of Infectious and Tropical Diseases. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 419-425.	1.5	5
36	Relationship among body mass index, NT-proBNP, and mortality in decompensated chronic heart failure. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2017, 46, 172-177.	1.6	4

#	ARTICLE	IF	CITATIONS
37	Transient myocardial ischemia in patients with chronic angina: relation to heart rate changes and variability in exercise threshold. <i>International Journal of Cardiology</i> , 1995, 49, 215-223.	1.7	3
38	Amino-terminal Pro-B-type Natriuretic Peptide for Risk Prediction in Acute Decompensated Heart Failure. <i>Congestive Heart Failure</i> , 2012, 18, 308-314.	2.0	2
39	Incremental utility of prognostic variables at discharge for risk prediction in hospitalized patients with acutely decompensated chronic heart failure. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2016, 45, 212-219.	1.6	2
40	Application of competing risks analysis improved prognostic assessment of patients with decompensated chronic heart failure and reduced left ventricular ejection fraction. <i>Journal of Clinical Epidemiology</i> , 2018, 103, 31-39.	5.0	2
41	Efficacy and duration of action of sustained-release diltiazem in patients with chronic stable effort angina. <i>Current Therapeutic Research</i> , 1993, 54, 672-679.	1.2	0
42	Comparison of a fixed combination of nifedipine slow release and atenolol (Bay-R-1999) and nifedipine slow release alone in patients with stable angina pectoris: A multicenter, randomized, double-blind, parallel-group study. <i>Current Therapeutic Research</i> , 1995, 56, 1175-1184.	1.2	0